PubMed:32464097 JSONTXT

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T1","span":{"begin":91,"end":99},"obj":"SP_7"},{"id":"T2","span":{"begin":101,"end":112},"obj":"NCBITaxon:11118"},{"id":"T3","span":{"begin":127,"end":135},"obj":"SP_7"},{"id":"T4","span":{"begin":168,"end":215},"obj":"SP_7"},{"id":"T5","span":{"begin":181,"end":192},"obj":"UBERON:0001004"},{"id":"T6","span":{"begin":217,"end":227},"obj":"SP_7"},{"id":"T7","span":{"begin":490,"end":503},"obj":"NCBITaxon:11118"},{"id":"T8","span":{"begin":505,"end":513},"obj":"SP_10"},{"id":"T9","span":{"begin":518,"end":526},"obj":"SP_9"},{"id":"T10","span":{"begin":747,"end":752},"obj":"SP_6"},{"id":"T11","span":{"begin":747,"end":752},"obj":"NCBITaxon:9606"},{"id":"T12","span":{"begin":753,"end":766},"obj":"NCBITaxon:11118"},{"id":"T13","span":{"begin":833,"end":841},"obj":"SP_7"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.\nCoronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Without approved antiviral therapeutics or vaccines to this ongoing global threat, type I and type III interferons (IFNs) are currently being evaluated for their efficacy. Both the role of IFNs and the use of recombinant IFNs in two related, highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, have been controversial in terms of their protective effects in the host. In this review, we describe the recent progress in our understanding of both type I and type III IFN-mediated innate antiviral responses against human coronaviruses and discuss the potential use of IFNs as a treatment strategy for COVID-19."}